-
Fils dominates Cobolli to book Cincinnati final
-
Coach Rennie hails clinical All Blacks after Springboks Test win
-
Spurs lacked fight in dismal defeat at Brentford says De Zerbi
-
Charlton deliver blow to 'under pressure' Hammers boss Nuno
-
Inter thrash Monza to launch Serie A title defence
-
Carrick keeps calm despite Man Utd misery, big-spending Spurs crushed
-
Shambolic Spurs battered by Brentford
-
Canada's Carney stands up to Trump, despite risks
-
Pogacar wins Vuelta a Espana opening stage
-
Lens hammer Auxerre thanks to Thauvin penalty double
-
Clinical New Zealand shock wasteful South Africa in first Test
-
No singles for Serena, but she joins Alcaraz for US Open
-
Canada hits back with new tariffs after trade talks with US fail
-
Joao Pedro extends Chelsea stay with new long-term deal
-
Swedish police identify 17-year-old girl as victim in school sword attack
-
Yamaguchi to face An in hunt for fourth badminton world crown
-
Carrick keeps calm despite Man Utd misery, Sage beaten in first game as Palace boss
-
Norris clinches pole for Dutch GP
-
France to deliver interceptor missiles to Ukraine after new Russian strikes
-
Norris clinches pole for Dutch Grand Prix
-
Serena Williams and Alcaraz unite in US Open mixed doubles
-
Pope Leo calls for courage in Rimini visit after stop in tiny San Marino
-
Macron pledges air defence as 13 killed in Russia, Ukraine strikes
-
Man Utd must learn from 'frustrating' defeat at Hull: Carrick
-
DR Congo capital wary of Ebola nightmare
-
Yamaguchi on course for fourth badminton world crown
-
Swedish police name 17-year-old girl as victim in school sword attack
-
Man Utd humiliated by Hull in dismal start to Premier League season
-
South Korea sends first container ship through Arctic route
-
Anthropic market debut could break SpaceX IPO record: media
-
Trescothick eager to keep England job despite Hussey approach
-
Pope's 'couturier of the sacred' fueled by faith
-
Indonesia deploys hundreds of soldiers to tackle Borneo fires
-
Duplantis locked in on 'grinding' for big bars
-
The last lap: Fans, drivers bid fond farewell to Dutch GP
-
Stokes says decision to leave Headingley off Ashes roster 'shambolic'
-
Silesia Diamond League: four events to watch
-
New arrival Rodri to miss Elche opener: Barca's Flick
-
Russell wins Dutch GP sprint race, Antonelli fourth
-
Atletico's Alvarez to return against Villarreal: Simeone
-
Mercedes driver George Russell wins Dutch GP sprint race
-
Dozens of civilians killed, kidnapped as jihadists clash in Nigeria
-
Ukraine strikes kill two children after Russia's deadly mall attack
-
Former envoys urge joint French, UK action on Palestinian territories
-
Pope visits San Marino, before addressing Italian political gathering
-
Australia lead by 101 in 2nd Bangladesh Test as 18 wickets fall on day one
-
Trump tariffs heap up as Canada tries to curb US reliance
-
'Aura' battles leap from social media to Latin America streets
-
Australia lose three wickets after skittling Bangladesh for 64
-
US, Canada fail to reach trade pact to avert Trump tariffs
MYTRT Announces UK Digital Healthcare Platform for Testosterone Testing and Doctor-Led Hormonal Health Services
LONDON, UK / ACCESS Newswire / May 23, 2026 / MYTRT, a UK-based digital healthcare platform, has announced the launch of a service for people seeking information, testing and clinical assessment relating to hormonal health. The platform includes home blood testing options, clinical review of results and care pathways for men who may require further assessment for low testosterone.

The service has been developed to support men who want to understand whether symptoms such as tiredness, low mood, reduced libido or changes in concentration may be associated with testosterone levels. These symptoms can have a range of causes, and MYTRT's pathway is intended to provide structured testing, result interpretation and next-step guidance from healthcare professionals.
MYTRT's testosterone testing service includes a home blood test option that measures testosterone-related biomarkers. Results are reviewed as part of a clinical pathway, rather than being returned only as raw laboratory values. Where further assessment is appropriate, patients may be offered a consultation to discuss their results, medical history and available treatment options.
Testosterone Replacement Therapy, commonly referred to as TRT, is a medical treatment that may be prescribed for men who have symptoms and clinically confirmed low testosterone. Treatment decisions are made following clinical review and are based on the individual patient's circumstances, test results and medical history. MYTRT states that any treatment provided through its platform is supported by ongoing monitoring and follow-up.
How the MYTRT Care Pathway Works
The MYTRT pathway is designed to move patients through testing, clinical review and, where appropriate, ongoing care. Patients begin by selecting a blood testing option. After the sample has been analysed, the results are reviewed and explained through the platform. If the findings indicate that further assessment may be needed, patients can discuss the results with a clinician and consider the next steps.
For patients who are already receiving testosterone replacement therapy, MYTRT also provides a transfer pathway into its doctor-led service. The pathway is intended for men who wish to have their existing treatment reviewed and monitored through a structured clinical service. Patients are assessed individually before any treatment or monitoring plan is agreed.
Doctor-Led Hormonal Health Support
"We created MYTRT to provide a structured route for people who want to understand their hormonal health and, where clinically appropriate, access doctor-led care," said Dr Raphael Olaiya, GP and TRT Doctor at MYTRT. "Our focus is on helping patients understand their results, receive clear guidance and make informed decisions with clinical support."
MYTRT states that each patient pathway is based on clinical assessment, result interpretation and ongoing monitoring. Treatment options may include topical, oral or injectable medication where these are clinically appropriate. Individual suitability, treatment choice and follow-up requirements are considered as part of the consultation and monitoring process.
Broader Biomarker Testing
Alongside testosterone testing, MYTRT offers wider biomarker testing options for people who want a broader view of selected health markers. These tests are available to both men and women and may be used to support discussions with healthcare professionals about general health, lifestyle and follow-up assessment.
Patients who complete broader testing can use their results to inform conversations with their own healthcare provider or seek further clinical guidance through the MYTRT platform. The company states that the service is intended to support information, monitoring and clinical decision-making rather than replace emergency, urgent or in-person medical care where that is required.
About MYTRT
MYTRT is a UK-based digital healthcare platform providing hormonal health services, including testosterone testing, clinical review and doctor-led care pathways. The platform supports men seeking assessment for low testosterone and offers wider biomarker testing for people who want additional health information. MYTRT's services are designed to combine home testing, result interpretation and ongoing clinical support where appropriate.
For more information, visit https://www.mytrt.com.
Media Contact
Organization: MYTRT
Contact Person Name: Raphael Olaiya
Website: https://www.mytrt.com/
Email: [email protected]
City: London
Country: United Kingdom
SOURCE: MYTRT
View the original press release on ACCESS Newswire
A.Williams--AT